These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2407231)

  • 21. Nonsteroidal anti-inflammatory drugs: how do they damage gastroduodenal mucosa?
    Scarpignato C
    Dig Dis; 1995 Jan; 13 Suppl 1():9-39. PubMed ID: 7697906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effects of azapropazone on cellular events at inflamed sites. Influence on joint pathology in arthritic rats, leucocyte superoxide and eicosanoid production, platelet aggregation, synthesis of cartilage proteoglycans, synovial production and actions of interleukin-1 in cartilage resorption correlated with drug uptake into cartilage in-vitro.
    Rainsford KD; Davies A; Mundy L; Ginsburg I
    J Pharm Pharmacol; 1989 May; 41(5):322-30. PubMed ID: 2569519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Kinetics of digitoxin during antirheumatic therapy with azapropazone (author's transl)].
    Faust-Tinnefeldt G; Gilfrich HJ
    Arzneimittelforschung; 1977; 27(10):2009-11. PubMed ID: 579114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction between azapropazone and warfarin.
    Powell-Jackson PR
    Br Med J; 1977 May; 1(6070):1193-4. PubMed ID: 861532
    [No Abstract]   [Full Text] [Related]  

  • 25. [Use of azapropazone in dental surgery].
    Perrini F; Cocchi G
    Dent Cadmos; 1979 Nov; 47(11):56-60. PubMed ID: 297567
    [No Abstract]   [Full Text] [Related]  

  • 26. Distribution of azapropazone and its principal 8-hydroxy-metabolite in plasma, urine and gastrointestinal mucosa determined by HPLC.
    Rainsford KD
    J Pharm Pharmacol; 1985 May; 37(5):341-5. PubMed ID: 2862244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage.
    Blandizzi C; Fornai M; Colucci R; Natale G; Lubrano V; Vassalle C; Antonioli L; Lazzeri G; Del Tacca M
    World J Gastroenterol; 2005 Jul; 11(26):4052-60. PubMed ID: 15996031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection from gastrointestinal side-effects by azapropazone by its incorporation into a glucose-sodium acid citrate formulation.
    Rainsford KD; Dieppe PA; Pritchard MH; Rhodes J; Leach H; Russell RI; Walker FS; Upadhyay R; Hort JF
    Aliment Pharmacol Ther; 1991 Aug; 5(4):419-33. PubMed ID: 1777551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of azapropazone on pain-related brain activity in human subjects.
    Lötsch J; Mohammadian P; Hummel T; Florin S; Brune K; Geisslinger G; Kobal G
    Br J Clin Pharmacol; 1995 Dec; 40(6):545-52. PubMed ID: 8703660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of azapropazone on the binding of warfarin to human serum proteins [proceedings].
    McElnay JC; D'Arcy PF
    J Pharm Pharmacol; 1978 Dec; 30 Suppl():73P. PubMed ID: 32332
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics of azapropazone in the elderly.
    Ritch AE; Perera WN; Jones CJ
    Br J Clin Pharmacol; 1982 Jul; 14(1):116-9. PubMed ID: 7104163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azapropazone (Rheumox).
    Drug Ther Bull; 1976 Dec; 14(26):102-3. PubMed ID: 795626
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of anti-inflammatory and analgesic pyrazoles on arachidonic acid metabolism in isolated heart and gastric mucosa preparations.
    Coersmeier C; Wittenberg HR; Aehringhaus U; Dreyling KW; Peskar BM; Brune K; Peskar BA
    Agents Actions Suppl; 1986; 19():137-54. PubMed ID: 3092600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of prostaglandin potentiated formalin induced arthritis with non-steroid antiphlogistics.
    Szántó L; Tanka D; Kellner M
    Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):113-9. PubMed ID: 1254374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.
    Verbeeck RK
    Clin Pharmacokinet; 1990 Jul; 19(1):44-66. PubMed ID: 2199127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and Biological Evaluation of Mutual Prodrugs of Carboxylic Group Containing Some Non-Steroidal Anti-Inflammatory Drugs and Propyphenazone.
    Paliwal M; Sucheta ; Ruchita ; Jain S; Monika ; Himanshu
    Curr Drug Deliv; 2017; 14(8):1213-1224. PubMed ID: 28201966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcers: role of mucosal protective and gastric antisecretory drugs.
    Dajani EZ; Agrawal NM
    Dig Dis; 1995 Jan; 13 Suppl 1():48-61. PubMed ID: 7697902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Some new aspects of gastric mucosal protection and damage.
    Bennett A
    Acta Physiol Hung; 1989; 73(2-3):179-83. PubMed ID: 2688358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The problems and pitfalls of NSAID therapy in the elderly (Part I).
    Johnson AG; Day RO
    Drugs Aging; 1991 Mar; 1(2):130-43. PubMed ID: 1794009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats.
    Tachibana M; Inoue N; Yoshida E; Matsui M; Ukai Y; Yano J
    Pharmacology; 2003 Jun; 68(2):96-104. PubMed ID: 12711837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.